Efficacy of Pentasa tablets for the treatment of XXXX .

@entity1 @entity31 @entity29 @entity3504 @entity21049 @entity30 @entity2983
BACKGROUND AND PURPOSE: The @entity21049 formulation of delayed-release @entity2983 ( @entity3504 ), @entity2983 tablets (AT), has limited efficacy in maintaining remission in @entity1 with @entity29 ( @entity29 ). This study evaluated the effect of switching @entity1 with unsatisfactory results under treatment with AT to a microgranule delayed-release formulation of @entity3504 , Pentasa tablets (PT). METHODS: A 12-week, open drug-switching study was conducted in 15 @entity29 @entity1 , including 9 with @entity31 ( @entity31 ) and 6 with @entity30 ( @entity30 ) who were evaluated at the time of switching from routine AT (2.4 g/day) treatment (for more than 3 months) to PT (4 g/day). @entity31 @entity1 were those under AT remission maintenance and they were defined as prone-to-relapse because of endoscopy scores > or = 2. @entity30 @entity1 were those under acute treatment with AT who had not attained a complete remission. The primary endpoint was the change in @entity31 Disease Activity Index ( @entity31 -DAI) or the @entity30 Activity Index scores after switching to PT therapy. Drug safety profile and @entity1 acceptability were secondary endpoints. RESULTS: Twelve weeks after switching to PT treatment, the mean (+/- SEM) @entity31 -DAI score was reduced significantly, from 8.18 +/- 0.58 to 6.81 +/- 0.72 (p = 0.013) in @entity31 @entity1 . Subcategory scores indicated improvements in endoscopy scores and in physician global assessment. Though the change in clinical outcomes did not reach significance for @entity30 @entity1 , a trend towards a therapeutic benefit was observed. No adverse event was observed during the 12-week clinical trial. CONCLUSION: PT may provide a better alternative for @entity29 @entity1 with unsatisfactory response to AT therapy.
